{"disease":{"id":"mpn","name":"mpn"},"drugs":{"marketed":[{"drug_id":"part-c-met097","indication_name":"Treatment of Myeloproliferative Neoplasms (MPNs)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT02252159","title":"Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)","phase":"","overall_status":"COMPLETED","enrollment_count":2544,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT02953704","title":"Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)","phase":"","overall_status":"COMPLETED","enrollment_count":1469,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT04064060","title":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":665,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT06211166","title":"Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT01178281","title":"Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":267,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT06740916","title":"Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT03611868","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT02393248","title":"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":201,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03613532","title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"Jacqueline Garcia, MD","has_results":false},{"nct_id":"NCT01633372","title":"An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT07384039","title":"Exercise Training in Patients With Myeloproliferative Neoplasms","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Hannover Medical School","has_results":false},{"nct_id":"NCT06753279","title":"Clinical Significance of Leukocyte Cell Population Data in Patients With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05677594","title":"Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT02718300","title":"A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT00726232","title":"Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04113616","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01348490","title":"Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT07298083","title":"DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05582902","title":"Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Leipzig","has_results":false},{"nct_id":"NCT04811196","title":"A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT05782985","title":"Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs","phase":"","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05817955","title":"Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT01393509","title":"The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03011372","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06849986","title":"IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05985161","title":"A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06735820","title":"Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"AeRang Kim","has_results":false},{"nct_id":"NCT04243122","title":"Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":false},{"nct_id":"NCT05253131","title":"Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":41,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT00004853","title":"Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05115344","title":"Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":31,"lead_sponsor_name":"Chengdu Zenitar Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT05153343","title":"Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Chengdu Zenitar Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT05123365","title":"An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"University of California, Irvine","has_results":false},{"nct_id":"NCT04473911","title":"Haplo Peripheral Blood Sct In GVHD Prevention","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Zachariah Michael DeFilipp","has_results":false},{"nct_id":"NCT03144687","title":"A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04187703","title":"5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Benjamin Tomlinson","has_results":false},{"nct_id":"NCT05642455","title":"SPEARHEAD-3 Pediatric Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"USWM CT, LLC","has_results":false},{"nct_id":"NCT03123588","title":"Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02211768","title":"Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04639024","title":"ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Gwynn Long, M.D.","has_results":false},{"nct_id":"NCT05612633","title":"A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Samus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04091295","title":"BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Aveni Foundation","has_results":false}],"total":44},"guidelines":[],"source":"Drug Landscape verified database"}